These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20407031)

  • 1. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
    LaPlant KD; Louzon PD
    Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G; Hutson TE; Sternberg CN
    Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
    Bukowski RM
    Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib for the treatment of renal cell carcinoma and other malignancies.
    Sonpavde G; Hutson TE; Sternberg CN
    Drugs Today (Barc); 2009 Sep; 45(9):651-61. PubMed ID: 19956806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
    Hsiao YW; Lin YC; Hui RC; Yang CH
    J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
    [No Abstract]   [Full Text] [Related]  

  • 11. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
    Sneed GT; Lee S; Brown JN; Hammond JM
    Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
    Penel N
    Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
    Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
    Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
    Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
    J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
    Frascaroli M; Di Cesare P
    Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.